The clinical and economic impact of surgical site infections after distal pancreatectomy.


Journal

Surgery
ISSN: 1532-7361
Titre abrégé: Surgery
Pays: United States
ID NLM: 0417347

Informations de publication

Date de publication:
06 2022
Historique:
received: 18 06 2021
revised: 20 10 2021
accepted: 11 11 2021
pubmed: 2 1 2022
medline: 1 6 2022
entrez: 1 1 2022
Statut: ppublish

Résumé

The present study aimed to evaluate surgical site infections' clinical and economic impact after distal pancreatectomy. The study was a prospective, monocentric, observational study, including all adult patients who underwent distal pancreatectomy. According to the American Centers for Disease Control and Prevention definition, the surgical site infection assessment was prospectively performed by trained personnel. The Accordion Severity Grading System was used to evaluate the clinical burden of surgical site infection. The hospitalization's total costs were calculated using the hospital expenditure report, excluding the intraoperative costs. During the study period, 414 distal pancreatectomies were performed. The overall incidence of surgical site infection was 26% (106 patients). Surgical site infections were associated with a higher body mass index (P = .022, odds ratio 1.2), positive preoperative rectal swab for multidrug resistant bacteria (P = .010, odds ratio 4.2), and increased operative time (P = .037, odds ratio 1.1). Using the Accordion Severity Grading System, surgical site infections contributed significantly to the total clinical burden (25.5%) and prolonged hospitalization (P < .001). Furthermore, surgical site infection doubled the costs (12.915 vs 6.888 euros, P < .001). Surgical site infection has a high clinical burden, negatively impacting the postoperative course. The costs and length of stay proportionally increased with the surgical site infection severity, doubling the hospitalization expenses.

Sections du résumé

BACKGROUND
The present study aimed to evaluate surgical site infections' clinical and economic impact after distal pancreatectomy.
METHODS
The study was a prospective, monocentric, observational study, including all adult patients who underwent distal pancreatectomy. According to the American Centers for Disease Control and Prevention definition, the surgical site infection assessment was prospectively performed by trained personnel. The Accordion Severity Grading System was used to evaluate the clinical burden of surgical site infection. The hospitalization's total costs were calculated using the hospital expenditure report, excluding the intraoperative costs.
RESULTS
During the study period, 414 distal pancreatectomies were performed. The overall incidence of surgical site infection was 26% (106 patients). Surgical site infections were associated with a higher body mass index (P = .022, odds ratio 1.2), positive preoperative rectal swab for multidrug resistant bacteria (P = .010, odds ratio 4.2), and increased operative time (P = .037, odds ratio 1.1). Using the Accordion Severity Grading System, surgical site infections contributed significantly to the total clinical burden (25.5%) and prolonged hospitalization (P < .001). Furthermore, surgical site infection doubled the costs (12.915 vs 6.888 euros, P < .001).
CONCLUSION
Surgical site infection has a high clinical burden, negatively impacting the postoperative course. The costs and length of stay proportionally increased with the surgical site infection severity, doubling the hospitalization expenses.

Identifiants

pubmed: 34972593
pii: S0039-6060(21)01146-6
doi: 10.1016/j.surg.2021.11.010
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1652-1657

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Matteo De Pastena (M)

Department of General and Pancreatic Surgery, The Pancreas Institute, University of Verona Hospital Trust, Italy.

Salvatore Paiella (S)

Department of General and Pancreatic Surgery, The Pancreas Institute, University of Verona Hospital Trust, Italy.

Michele Fontana (M)

Department of General and Pancreatic Surgery, The Pancreas Institute, University of Verona Hospital Trust, Italy.

Chiara Filippini (C)

Department of General and Pancreatic Surgery, The Pancreas Institute, University of Verona Hospital Trust, Italy.

Laura Addari (L)

Department of General and Pancreatic Surgery, The Pancreas Institute, University of Verona Hospital Trust, Italy.

Alice Giorgi (A)

Department of General and Pancreatic Surgery, The Pancreas Institute, University of Verona Hospital Trust, Italy.

Simona Canton (S)

Department of General and Pancreatic Surgery, The Pancreas Institute, University of Verona Hospital Trust, Italy.

Giovanni Zanusso (G)

Department of General and Pancreatic Surgery, The Pancreas Institute, University of Verona Hospital Trust, Italy.

Anna Maria Azzini (AM)

Infectious Diseases Unit, Department of Diagnostic and Public Health, University of Verona, Italy.

Claudio Bassi (C)

Department of General and Pancreatic Surgery, The Pancreas Institute, University of Verona Hospital Trust, Italy.

Evelina Tacconelli (E)

Infectious Diseases Unit, Department of Diagnostic and Public Health, University of Verona, Italy.

Roberto Salvia (R)

Department of General and Pancreatic Surgery, The Pancreas Institute, University of Verona Hospital Trust, Italy. Electronic address: roberto.salvia@univr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH